Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (DE:RHO5)
FRANKFURT:RHO5
RHO5 Stock Chart & Stats
€394.85
€0.00(0.00%)
At close: 4:00 PM EST
€394.85
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€244.35 - €395.50
Previous CloseN/A
Volume2.84K
Average Volume (3M)397.00
Market Cap
€315.77B
Enterprise Value€312.61B
Total Cash (Recent Filing)€15.48B
Total Debt (Recent Filing)€31.64B
Price to Earnings (P/E)22.9
Beta0.14
Next Earnings
Jul 23, 2026EPS Estimate
11.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.17
Shares Outstanding702,562,700
10 Day Avg. Volume250
30 Day Avg. Volume397
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€378.32Price Target Upside-4.19% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diabetes Device ExpansionEntry into continuous glucose monitoring with a differentiated device that integrates artificial intelligence and connects to the emerging GLP-1 treatment portfolio targets conversion of a large existing diabetes customer base and creates a new revenue stream.
Diagnostics InnovationA new high-speed genetic sequencing platform combined with a proprietary sensor chip could enable faster and more accurate testing, allowing the diagnostics division to challenge the market leader and drive meaningful growth.
Pipeline Clinical ProgressLate-stage positive readouts for fenebrutinib in relapsing multiple sclerosis and for giredestrant in the adjuvant breast cancer setting increase confidence in broader trials and support potential revenue upside if efficacy is confirmed.
Bears Say
Giredestrant Efficacy UncertaintyUncertainty about endocrine sensitivity for giredestrant in the first-line breast cancer setting leaves its commercial potential unclear and may slow clinician adoption.
Historical Trial RiskSeveral prior high-risk trials produced negative outcomes, sustaining investor caution and valuation pressure until a consistent pattern of successful readouts emerges.
Safety And Statistical Concerns For FenebrutinibLimited information on statistical significance and potential liver toxicity for fenebrutinib creates regulatory and clinical adoption risks that could delay approval or reduce market uptake.
Roche Holding AG News
RHO5 FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was €244.35 and its highest was €395.50 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is €315.77B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 156 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported €9.172 earnings per share for the quarter, missing the consensus estimate of €9.325 by -€0.153.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Overvalued.
Does Roche Holding AG pay dividends?
Roche Holding AG does not currently pay dividends.
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 11.78.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of €9.172 in its last earnings report, missing expectations of €9.325. Following the earnings report the stock price went up 3.63%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in DE:RHO5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHO5 Company Deck
RHO5 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong growth in pharmaceutical sales and robust pipeline development, particularly in oncology and neurology. However, challenges in the Diagnostics segment due to China's pricing reforms and mixed clinical trial results tempered the positive outlook. Additionally, regulatory setbacks and geopolitical uncertainties added caution.View all DE:RHO5 earnings summariesRHO5 Stock 12 Month Forecast
Average Price Target
€378.32
▼(-4.19% Downside)
Technical Analysis
Options Prices
Currently, No data available
---